New Alzheimer’s drug Aduhelm has no clinical benefit, panel of medical experts concludes
By
Alicia Lasek
Jul 21, 2021
The drug does not improve upon the current standard of care for Alzheimer’s disease, say advisers to the Institute for Clinical and Economic Review, a drug pricing watchdog.
Slow buy-in: Only 3% of neurologists have written Aduhelm prescriptions so far
By
Alicia Lasek
Jul 15, 2021
Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.
House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
AMDA: Don’t prescribe Aduhelm to long-term care residents without more testing
By
Alicia Lasek
Jul 01, 2021
“It is our responsibility to resist the urge to prescribe a potentially dangerous and ineffective medication that is untested in our population, even if it has FDA approval,” the LTC physician’s...